Purpose: Deregulation of key cellular pathways is fundamental for the survival and expansion of neoplastic cells. In cancer, regulation of gene transcription can be mediated in a variety of ways. The purpose of this study was to assess the impact of gene dosage on gene expression patterns and the effect of other mechanisms on transcriptional levels, and to associate these genomic changes with clinicopathologic parameters.
Copy number alterations (CNA) are a fundamental feature of neoplastic cells that influence crucial cancer-specific processes (1) . It is estimated that >1% of protein-coding genes in the human genome contribute to tumorigenesis, whereas only 3% of these have been implicated in sporadic breast carcinoma (2) . In comparison with many tumor types of nonepithelial origin, breast carcinomas arising from epithelial cells have numerous genetic alterations (3) . Many of the recurrent alterations occurring in carcinomas of the breast have been identified, including copy number gains on 1q, 8p, 8q, 11q, 16p, 17q, and 20q, and losses on 1p, 6q, 11q, 16q, 17p, and 22q (4).
However, tumorigenesis is a dynamic evolutionary process that promotes genetic heterogeneity and thereby produces a complex combination of random and nonrandom aberrations. To study complex phenotypes such as cancer, a straightforward approach is to provide comprehensive information on the disease by integrating multiple platforms on several biological levels (DNA-RNA-protein). Integrative analyses of data produced by genome-wide profiling techniques such as array comparative genomic hybridization (array-CGH; ref. 5 ) and expression microarrays can provide detailed information on the genomic locations of recurrently altered DNA regions, the impact of these CNAs on gene deregulation, as well as enhance our understanding of these genetic events coupled with clinicopathologic parameters (6, 7) . However, there are limitations associated with the array-CGH approach as it will not detect inversions, balanced translocations, polyploidy, mutations, or epigenetic modulations. It is, therefore, necessary to also study changes in gene expression patterns independent of CNA.
In the present investigation, we chose to conduct genome-wide screening on a series of diploid breast carcinomas (DBC). A previously suggested theory postulated that the aneuploid state is not fundamental to malignancy as diploid and aneuploid breast tumors share many of the acquired genetic aberrations characteristic of the disease, despite the increase in number of events in aneuploid disease (8) (9) (10) (11) (12) (13) (14) . Approximately 1 in 4 diagnosed breast carcinoma cases have a diploid DNA content (15) . Generally, diploid tumors are composed of a nearly homogenous mix of slow-growing cells that may permit these neoplasms to follow a more favorable clinical course than aneuploid tumors (16, 17) . The more aggressive phenotype displayed by aneuploid tumors can possibly be explained by clonal heterogeneity represented by the presence of fewer cells expressing the steroid hormone receptors, increased proliferative activity, and a higher percentage of poorly differentiated tumors (18) . Taken together, these observations suggest that despite diversity there are similar molecular mechanisms active in the development of breast carcinomas, regardless of ploidy status. Thus, it is of particular interest to conduct integrative genomics using diploid breast carcinomas to mitigate some of the obstacles associated with the heterogeneity of genetic alterations in carcinomas.
Therefore, we investigated the copy number-and non-CNA-induced gene expression patterns of DBC from 97 patients using 38K BAC array-CGH and the Illumina HumanHT-12 platform. With the application of this approach on a series of DBC we were able to reduce biological noise and thereby identify key putative candidate genes associated with an aggressive phenotype in breast carcinoma. Additionally, we were able to develop an approach to (a) test the relationship between gene dosage and mRNA levels, (b) determine the proportional or nonproportional gain/loss in CNA and gene expression patterns, and (c) determine if a significant difference in expression levels exists between neoplasms possessing a given genetic aberration and those lacking these aberrations.
Materials and Methods

Patient and tumor specimens
Primary invasive tumors from 97 DBC patients were selected from the fresh-frozen tissue tumor bank at the Sahlgrenska University Hospital Oncology Lab (Gothenburg, Sweden). Patient stratification according to axillary lymph node status (node-negative, pN 0 ; nodepositive, pN 1 ) and overall survival (>8-year survivors, henceforth termed long-term survivors; breast cancerspecific mortality within 8 years of diagnosis, henceforth termed short-term survivors) is shown in Supplementary  Table S1 . All samples were assessed for DNA content at the time of diagnosis from 1991 to 1999 (data not shown) by flow cytometry at the Laboratory for Clinical Chemistry, Sahlgrenska University Hospital. Tumor specimens with a DNA index of 1.0 were classified as diploid. The presence of malignant cells was assessed in all samples by evaluation of touch preparation imprints stained with May-Grünwald Giemsa (Chemicon). Highly representative specimens possessing >70% neoplastic cell content were included in the microarray and fluorescence in situ hybridization (FISH) analyses. All procedures were done in accordance with the Declaration of Helsinki and approved by the Medical Faculty Research Ethics Committee (Gothenburg, Sweden). The clinicopathologic features of the 97 cases are shown in Table 1 .
Array-CGH
Whole-genome tiling arrays with 38,043 reporters mapping to the UCSC May 2004 hg17: NCBI Build 35 were manufactured as previously described (19) at the SCIBLU Genomics DNA Microarray Resource Center (SCIBLU), Department of Oncology, Lund University. Images and raw signal intensities were acquired using an Agilent G2505B DNA microarray scanner (Agilent Technologies) and GenePix Pro 6.0.1.22 (Axon Instruments) image analysis software.
Data preprocessing and normalization were done using the web-based BioArray Software Environment system (BASE) provided by SCIBLU (ref. 20 ; http://base2.thep. lu.se/onk/). Further analysis to segment the data into regions of gains and losses was done using the Rank Segmentation algorithm with Nexus Copy Number Professional 4.1 software (BioDiscovery), as previously described (21) . Further, log 2 ratio thresholds for low-level gain (LLG), high-level gain/amplification (HLG), heterozygous loss (HL), and homozygous deletion (HD) were set at +0.2, ≥+0.5, -0.2, and ≤-1.0, respectively, using a P value cutoff of 0.01. Genomic regions covered entirely by previously reported copy number variations in the human genome were removed (22) . Unsupervised hierarchical clustering was applied using complete linkage with Pearson correlation to group tumors based on detected genetic alterations (LLG and HL). The association between clinicopathologic features and CNAs was analyzed using a P value cutoff of 0.05 with the Mann-Whitney U or Kolmogorov-Smirnov test, as appropriate.
Translational Relevance
This study provides novel information on the specific DNA copy number aberrations and underlying changes in gene expression associated with clinicopathologic features in diploid breast carcinoma. Using an integrative genomics approach, we identified transcripts whose expression patterns were directly impacted by gene dosage. In addition, the transcriptional levels of 12 genes were consistently associated with a more malignant phenotype in diploid breast carcinoma. Integrating data on DNA and mRNA dysregulation in relation to breast cancer behavior is, therefore, a step toward understanding tumor initiation and progression contributing to unfavorable prognosis. Furthermore, these findings provide potential targets in the development of individualized patient therapy for aggressive breast neoplasms. Verification of HER2/neu gene amplification using FISH Dual-color FISH was done to confirm HER2/neu gene amplification in tumors with positive (log 2 ratio ≥+0.5) array-CGH results (11%). Touch preparation imprints were prepared from fresh cuts of frozen tumor samples on Superfrost Plus microscope slides (Erie Scientific Company). Probe hybridization and posthybridization washes were done according to the manufacturer's guidelines using the ZytoLight SPEC HER2/CEN 17 Dual Color Probe (ZytoVision GmbH). The slides were evaluated using a Leica DMRA2 fluorescence microscope (Leica) equipped with an ORCA Hamamatsu charged-couple devices camera (Hamamatsu Corporation). Digitalized black-and-white images were captured at ×100 magnification using the Leica CW4000 software package (Leica Microsystems Imaging Solutions Ltd). HLG was classified in cells with ≥2.5-fold the centromere count.
Gene expression analysis
Total RNA from the same extraction was used for both expression profiling and subsequent validation with quantitative real-time PCR. The RNA samples were processed at SCIBLU using Illumina HumanHT-12 Whole-Genome Expression BeadChips (Illumina), according to the manufacturer's instructions. The expression microarrays contained approximately 49,000 probes representing >25,400 RefSeq (Build 36.2, Release 22) and Unigene (Build 199) annotated genes. Images and raw signal intensities were acquired using the Illumina BeadArray Reader scanner and BeadScan 3.5.31.17122 (Illumina) image analysis software, respectively.
Data preprocessing and quantile normalization were applied to the raw signal intensities using BASE. Further data processing was done in Nexus Expression 2.0 (BioDiscovery) using log2-transformed, normalized expression values and a variance filter. Normalized values from five normal breast samples profiled with Illumina HumanWG-6 Expression Beadchips (GEO, accession number GSE17072) were used as reference (23) . Differentially expressed genes were determined using the Benjamini-Hochberg method (24) to control for the false discovery rate (FDR) with FDR-corrected P values <0.01. The diploid dataset was stratified into the molecular breast cancer subtypes using the five centroids [normal-like, basal-like, luminal subtype A, luminal subtype B, and human epidermal growth factor receptor 2/estrogen receptor negative (HER2/ER-)] and genomic grade index (GGI; low, high) using estrogen receptor-positive tumors as previously described (25) (26) (27) . All microarray data discussed in this publication are accessible through the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO accession number GSE20486; http://www.ncbi.nlm.nih.gov/ geo/query/acc.cgi?acc=GSE20486).
Quantitative real-time PCR
Validation of the expression microarray data was done as previously described using quantitative real-time PCR (qPCR) with predesigned TaqMan Gene Expression Assays (Applied Biosystems; ref. 28) . In brief, 82 of 97 total RNA samples were used to validate the expression patterns of 16 transcripts and 3 endogenous controls, i.e., PPIA, PUM1, and HPRT1. The endogenous controls were selected based on their constitutive expression using the Illumina HumanHT-12 platform. The geometric mean of the three endogenous controls was used to normalize the data, and relative gene expression levels were calculated with the relative standard curve method. Student's t-test was used to determine the difference in expression between studied groups, and the Spearman correlation coefficients (two-tailed) were calculated to establish the relationship between microarray and qPCR expression patterns.
Integrated DNA copy number and expression analysis
Illumina HumanHT-12 probe nucleotide sequences were mapped to genomic locations (NCBI Build 35) using sequences downloaded from the UCSC Genome Browser (ref. 29 ; http://hgdownload.cse.ucsc.edu/goldenPath/ hg17/chromosomes/). A pairwise comparison of the Illumina probe and BAC clone nucleotide sequences was then conducted to generate Illumina-BAC probe pairs with 100% sequence similarity. Illumina-BAC probes spanning the recurrent aberrations were selected from smoothed array-CGH data using log 2 ratio ± 0.2. CNA-induced genes were assessed by Pearson correlation (Q< 0.05). Further, the change in mRNA levels as a function of DNA copy 
Results
Overview of chromosomal aberrations detected by array-CGH in the diploid patient population Ninety-seven diploid breast tumors were analyzed for DNA copy number alterations using 38K BAC CGH arrays. Chromosomal aberrations were detected in all tumors, including all human autosomes and the X chromosome. These segments varied in size from small aberrations to gain and/or loss of whole chromosomes (range, 103 kb to 109 Mb; mean, 6.6 Mb). The mean number of DNA copy number alterations (± SEM) corresponding to clinicopathologic features are presented in Supplementary  Table S2 . On average, 40.1 ± 3.9 chromosomal aberrations (range, 2-204) were detected per diploid tumor sample, including 20.1 ± 2.0 LLG (range, 0-117), 4.9 ± 0.6 HLG (range, 0-31), 15.1 ± 1.7 HL (range, 0-104), and 0.03 ± 0.02 HD (range, 0-1). Recurrent regions of gains and losses observed with a frequency of ≥25% (P < 0.01) were identified using the Rank Segmentation algorithm in Nexus Copy Number 4.1 (Fig. 1A) . LLG was observed on nine chromosomal subregions on 1q22 (53%), 1q22-q23.1 (53%), 1q25.3 (53%), 1q32.1 (53%), 1q32.1-q32.2 (53%), 8q21.2-q21.3 (33%), 8q22.3 (26%), 8q24.3 (26%), and 16p11.2 (26%). Loss was observed on six subregions on 11q25 (26%), 16q21 (38%), 16q23.3 (38%), and 17p12 (26%). Recurrent regions of HLG in at least 10% (P < 0.01) of the cases were identified on three subregions on 1q32.1 (20%), 1q32.2 (20%), and 11q13.3-q13.4 (10%). In addition, several amplicons were detected in <10% of the patient population, i.e., 3q26.2 (5%), 8p11-p12 (6%), 8q (5-9%), 17q (5-9%), and 20q13 (6%; Fig. 1B ). These findings are consistent with published array-CGH data on breast carcinoma (9, (30) (31) (32) (33) (34) (35) and are listed in more detail in Table 2 .
Unsupervised clustering of the dataset according to the detected LLG and HL in each tumor produced two distinct groups. Cluster 1 (n = 21) contained tumors displaying very few aberrations in select portions of the genome Fig. 1 . Genome-wide frequency plots of gains and losses in 97 DBC samples. X-axis, genomic region from chromosome 1 to X; Y-axis, percentage of gains and losses. Green, dark green, and red bars, percentage of LLG, HLG, and HL in the given chromosomal region, respectively. A, the frequency of LLG, HLG, and HL in DBC. B, schematic overview of HLG in DBC. Statistically significant regions (P < 0.01) present in ≥10% of DBC samples are indicated with black arrows showing candidate genes located in the region. Red arrows, previously reported genomic regions in breast cancer, present in <10% of DBC samples. C, top, green and red, statistically significant regions (≥25% difference). Bottom, frequency of CNAs for the two clusters generated by unsupervised hierarchical clustering using complete linkage with Pearson correlation.
including exclusion of 1q gain, which is common in most breast neoplasms, whereas cluster 2 (n = 76) contained tumors with an abundance of genetic aberrations covering the entire genome (Fig. 1C) . In addition, the former group lacked genetic alterations on chromosomes 3, 18, and 20, and loss of chromosome 6 was more characteristic of this group. In general, cluster 1 consisted predominantly of low-grade tumors (P = 0.006), low GGI (P = 0.021), and long-term survivors (P = 0.034), whereas cluster 2 consisted predominantly of tumors from short-term survivors (P = 0.034), high GGI (P = 0.035), short-term survivors with pN 1 disease (P = 0.044), and tumors with gain of the 8p11-p12 locus (P = 0.044).
Correlation of DNA copy number alterations to clinicopathologic features
To determine if clinicopathologic features are characterized by specific genetic alterations, recurrently altered genomic regions were compiled and are shown in Supplementary Table S3 . A high number of genetic alterations were observed in tumors with high GGI (P = 0.0004), tumors from short-term survivors (P = 0.001), cluster 2 (P = 0.001), and high-grade tumors (P = 0.007), in comparison with their corresponding counterparts. Specifically, a higher number of LLG (P = 0.001), HLG (P = 0.005), and HL (P = 0.005) were detected in short-term survivors compared with long-term survivors, suggesting that the number of genetic alterations may have a detrimental effect on clinical outcome. Using the Rank Segmentation algorithm and a 25% difference cutoff, HL on 3p14.2, 17p13.1-p12, and 18q23 was more prevalent in short-term survivors than in long-term survivors. Further, LLG and HLG were generally more frequent in high-grade than in low-grade tumors (P = 0.002 and P = 0.01, respectively). All forms of genetic aberrations, excluding HD, were more prevalent in tumors with high than low GGI. LLG (P = 0.04) was more prevalent in larger tumors (pT 3 /pT 4 ) than in smaller tumors (pT 1 / pT 2 ). LLG and HLG were generally more frequent in cluster 2 than in cluster 1 (P = 0.00003 and P = 0.02, respectively). LLG of the 17q23.3-q24.1 region was detected solely in high-grade and never in low-grade tumors. With respect to GGI status, LLG of 1q, 20q and HL of 3p14.2, 8p, 11q, 17p12-p11.2, and 18q23 were more prevalent in high GGI tumors. Lastly, LLG on chromosomes 2q, 7p, 12q, 17q, and 20q was observed predominantly in larger tumors.
In our dataset, there was no distinct difference in the number of or type of observed CNAs in tumors with regard to their axillary lymph node status. These findings suggest that pN 0 and pN 1 tumors are biologically similar entities. Biological differences became apparent when these tumors were further stratified by either overall survival status and/or by the number of positive axillary lymph nodes (PALN). LLG of 6p21.32-p21.31 and HL of 10q26.12 were more prevalent in short-term survivors with pN 0 tumors than in short-term survivors with pN 1 tumors. Furthermore, heterozygous loss of 8p23.2 was predominantly detected in tumors from patients with four or more PALN than pN 0 tumors. LLG of 8p12 was more prevalent in long-term survivors with one to three PALN than long-term survivors with pN 0 tumors; LLG of the 6p25.3 and 17q12-q21.2 regions was more prevalent in long-term survivors with four or more PALN than in long-term survivors with pN 0 tumors; lastly, LLG of 17q12-q21.2 was more prevalent in long-term survivors with four or more PALN than in long-term survivors with one to three PALN. To validate the array-CGH results, dual-color interphase FISH was done on tumors displaying HLG of the HER2/neu gene using the ZytoLight SPEC HER2/CEN 17 Dual Color Probe. We observed a 100% concordance between array-CGH and FISH for the assessment of HER2/neu amplification (Fig. 2) .
Gene expression profiling
The numbers of deregulated transcripts in each group comparison identified by transcriptome profiling of the DBC samples, as well as Gene Ontology biological processes associated with these genes, are shown in Table 3 . A large number of transcripts were deregulated 1.5-fold based on short-term overall survival, endocrine insensitivity, high GGI, and triple-negative status. Similar to results on the DNA level, there were few differences between tumors stratified according to axillary lymph node status, as only the CNTNAP2 gene was differentially expressed. Similarly, few transcripts differed statistically between tumors of varying Scarff-Bloom-Richardson (SBR) grade, implying that there may be some overlap between SBR grade II and low-and high-grade tumors. One gene (SHISA2) was upregulated in SBR grade I compared with grade II tumors, which was also among transcripts differentially regulated between SBR grade I and grade III tumors. Six genes were on both lists for SBR grade I versus III and SBR grade II versus III (S100A8, S100A9, CBX2, MAPT, AZGP1, PIP). Lastly, a comparison of the gene expression levels was done on the two clusters determined using genetic alterations. In total, five transcripts were differentially regulated (two upregulated and three downregulated). These results show the recurrent upregulation of transcripts associated with a more malignant phenotype (short-term overall survival, endocrine insensitivity, triple-negative status, poor tumor differentiation), i.e., UBE2C, S100A8, and CBX2, whereas LOC389033, STC2, DNALI1, SCUBE2, NME5, SUSD3, SERPINA11, AZGP1, and PIP are downregulated (Supplementary Table S4 ). Five of these genes were also differentially regulated between tumors of high and low GGI, i.e., UBE2C, S100A8, STC2, SCUBE2, and SERPI-NA11. To validate these results, 16 genes showing >1.5-fold differential expression levels in either the receptor status or overall survival groups were assessed with qPCR. A linear relationship was found between the Illumina and qPCR results (r S = 0.97; P < 0.01). The results of the validation experiments are listed in Supplementary Table S5 .
Stratification of the diploid dataset into molecular gene expression subtypes and GGI
The diploid dataset was stratified into the five molecular breast cancer subtypes by assigning each tumor to one of the five centroids using the Pearson correlation coefficient (25) . Subsequently, no tumors (0%) were classified as normal-like, whereas 7 (7%) were classified as basal-like, 1 (1%) as luminal subtype A, 78 (80%) as luminal subtype B, and 11 (11%) as HER2/ER-. As expected, all tumors classified as both HER2-positive and estrogen receptor-negative (n = 4) were correctly classified in the HER2/ ER-subtype. The remaining HER2-positive tumors were either classified in the HER2/ER-(n = 1) or the luminal subtype B groups (n = 6). In addition, basal-like (86%) and HER2/ER-(64%) tumors were predominantly associated with short-term overall survival; basal-like (67%) and HER2/ER-(73%) tumors were more prevalent in cluster 2 than in cluster 1. Eighty-one percent of tumors grouped in cluster 1 were of luminal B subtype. Stratification of the 81 estrogen receptor-positive tumors in our dataset into the GGI groups produced a slight overlap between the low and high GGI groups, whereas two SBR grade I and four grade III tumors were classified with high and low GGI, respectively. As expected, SBR grade II tumors were a mix of both GGI groups. In general, low GGI was predominantly associated with long-term overall survival (P = 0.008), long-term survivors with one to three PALN (P = 0.009), SBR grade I (P = 0.009), pT 1 (P = 0.012), cluster 1 (P = 0.02), and one to three PALN (P = 0.025), whereas high GGI was associated with four or more PALN (P = 0.001), short-term survivors with four or more PALN (P = 0.005), short-term survivors with pN 1 disease (P = 0.006), shortterm overall survival (P = 0.008), pT 2 (P = 0.018), and cluster 2 (P = 0.02).
Integrated DNA copy number and gene expression analysis
To determine the effect of CNAs on gene deregulation in DBC, a correlation analysis was done in three steps using identified CNAs. These analyses showed that the regulation of several breast cancer-related candidate genes and genes not previously associated with breast cancer were located within recurrent CNAs listed in Table 2 . In total, 1,161 Illumina-BAC probe pairs contained nucleotide sequences within the 18 observed CNAs, of which 149 probe pairs (52 unique genes and 3 Unigene clusters) were identified as having a significant correlation between DNA and relative mRNA levels (Supplementary Table S6 ). For 38 genes the expression levels were as expected given the CNA log 2-ratio; 3 genes showed higher expression levels and 14 genes showed lower expression levels than expected considering the CNA log 2 ratio. Comparison of relative mRNA levels between samples showing no CNAs and gain/loss of specific genomic regions identified 128 of 149 probe pairs (47 genes and 1 Unigene cluster) with significantly different expression levels between the two groups. Figure 3 illustrates an example of the integration analysis for the HER2/neu gene in amplified and nonamplified tumors.
Discussion
Our integrative genomics approach showed that diploid breast neoplasms exploit different strategies to promote tumorigenesis via gene deregulation. These results suggest that despite diversity DBCs contain common genetic anomalies that may mediate malignant tumor behavior. Furthermore, these observations support the theory that aberrant gene expression levels displayed in breast carcinoma are, in part, induced by CNAs and other mechanisms of transcriptional control (3).
CNAs are a common feature of genetic instability in breast carcinomas (3) . The finding that a progressive increase in genetic aberrations is seemingly predictive of unfavorable clinical outcome has been shown in several studies (12, 14) . In the present study, this pattern was associated with tumors exhibiting aggressive behavior, i.e., tumors originating from short-term survivors, larger tumors, poorly differentiated tumors, tumors with high GGI, and tumors grouped in cluster 2. The presence of recurrent genetic alterations at specific loci was also reflective of an adverse effect on patient clinical outcome. Among the recurrently altered regions identified here, transcripts on chromosome 1 are of particular interest, as we have shown that patients with tumors lacking genetic alterations on chromosomes 1, 3, 18, and 20 have better prognoses. Although CNAs are a fundamental feature of tumorigenesis, we have shown that changes in gene dosage do not necessarily relate to the amount of mRNA gene product.
To assess the clinical significance of disease-associated gene deregulation, we integrated copy number data with expression patterns. We were, therefore, able to show that only a fraction of the genes altered at the DNA level were actually transcribed at abnormal levels. Relative mRNA levels of 48 of 360 (13%) transcripts located within the 18 common regions of genetic alteration were directly impacted by CNAs, thus further emphasizing the notion that many genetic alterations are bystander mutations that may not reflect biological effect. These findings are consistent with previous reports, which showed that the percentage of overexpressed genes can range from 6% to 44% depending on the level of gene dosage (6, 7, 32) . However, the coregulation and expression of adjacent genes may play an important role in tumorigenesis (7) . To further characterize these transcripts, we showed a variation in the overall rate of gene transcription given a specific copy number. This may be a reflection of the robust induction of gene transcription, as a single gene must bypass several checkpoints before it is expressed. We hypothesize that transcripts with expression levels deviating from expected values (higher and lower) given gene dosage may be controlled by multiple molecular mechanisms including smaller CNAs not detected using BAC arrays.
Recurrent chromosomal regions of gain and amplification are common on 1q in several types of human neoplasms, ranging from carcinomas of the breast to sarcomas (36) . Here, we show that 40 of 48 (83%) of the transcripts correlating with gene dosage were located on chromosome 1q consisting of five clusters of adjacent genes. We find ARHGEF11, CLK2, DHX9, EFNA1, RAB7L1, RABIF, RAG1AP1, RIPK5, RNASEL, RNPEP, and SNRPE of particular interest as the elevated mRNA levels of these genes combined with increased copy number may promote oncogenic activity. Several of these genes regulate similar cellular processes predominantly involved in cell motility, protein amino acid phosphorylation, RNA splicing, and cell-cell signaling. Alternative cellular processes by which breast neoplastic cells mediate abnormal relative mRNA levels in this study are unclear. Interestingly, our data suggest the consistent deregulation of 12 genes, i.e., UBE2C, S100A8, CBX2, LOC389033, STC2, DNALI1, SCUBE2, NME5, SUSD3, SERPINA11, AZGP1, and PIP, in breast carcinomas with a malignant phenotype. Functional studies have implicated several of these genes in a role in tumor cell growth, motility, and progression in multiple cancer types (37) (38) (39) (40) (41) (42) (43) (44) . Here, we could associate all 12 genes with progesterone expression and 11 with estrogen expression (UBE2C Response to estradiol stimulus, regulation of cytokine biosynthetic process, regulation of inflammatory response, DNA replication checkpoint, positive regulation of interleukin-4 and 8 production, positive regulation of exit from mitosis, anti-apoptosis, cell-cell signaling, mammary gland development, regulation of cell proliferation, negative regulation of tumor necrosis factor production excluded). Similarly, Gruvberger et al. (45) identified S100A8 and STC2 as estrogen receptor antagonist and responsive genes. Furthermore, Berlingieri et al. (46) revealed that suppression of ERBB2 inhibits UBE2C activity and thereby cell growth. Another intriguing finding was the identification of a single transcript (CNTNAP2) differently deregulated between the axillary lymph node groups. This transcript spans 2.3 Mb of chromosome 7, which makes it the largest known gene in the human genome, and is also located at a region containing a common fragile site (FRA7I; refs. 47, 48). We did not, however, observe loss of the 7q35-q36.1 chromosomal region spanning the CNTNAP2 gene that could explain downregulation in pN 0 tumors. Expression of the CNTNAP2 protein has been primarily implicated in disorders of the vertebrate nervous system for its functions as cell adhesion molecules and receptors (49) . In cancer, the CNTNAP2 promoter has been shown to be hypermethylated in 82% of pancreatic cancers in comparison with 3% in normal pancreas (50) . Hypermethylation of the CNTNAP2 promoter may be one mechanism by which the transcriptional levels of this gene may be silenced. To determine the methylation status of this gene and to establish its role in breast tumor development and progression, further methylation studies using breast neoplasms are warranted.
In summary, we have shown the feasibility of using microarray technology as a tool to identify common biological features among breast carcinomas that can be used as potential therapeutic targets. We identified 18 recurrent regions of genetic alteration in our dataset, of which 48 transcripts were abnormally expressed. In addition, the expression levels of 12 genes displaying normal copy numbers were associated with malignant phenotypes in breast carcinoma. This approach identified good candidates for further investigations using an independent series of multiple cancer types to assess the biological relevance of elevated DNA and/or mRNA levels on protein gene product. Taken together, this information can potentially be used to establish cost-effective targeted and individualized treatment regimens that will directly benefit a specific patient based on the genetic/ transcriptomic profile of the associated tumor to target specific cellular pathways perturbed in the tumor without affecting the activity of nonneoplastic cells.
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